About NanoEntek
NanoEntek is a company based in Seoul (South Korea) founded in 2000. The company has 138 employees as of December 31, 2024. NanoEntek offers products and services including FREND™ System, EVE™ HT FL, ADAM™ MC Plus, ADAM™ rWBC HT, and ADAMII™. NanoEntek operates in a competitive market with competitors including GNA Biosolutions, NanoVation-GS, Tethis, Entopsis and ACXEL, among others.
- Headquarter Seoul, South Korea
- Employees 138 as on 31 Dec, 2024
- Stage Public
-
Sectors
HealthcareTechnology
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Nanoentek, Inc.
-
Annual Revenue
$20.65 M (USD)13.52as on Dec 31, 2024
-
Net Profit
$2.43 M (USD)0as on Dec 31, 2024
-
EBITDA
$2.22 M (USD)928.12as on Dec 31, 2024
-
Latest Funding Round
$8.43 M (USD), Post-IPO
Aug 20, 2015
-
Investors
Not available
-
Employee Count
138
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of NanoEntek
NanoEntek is a publicly listed company on the KRX with ticker symbol 039860 in South Korea, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of NanoEntek
NanoEntek offers a comprehensive portfolio of products and services, including FREND™ System, EVE™ HT FL, ADAM™ MC Plus, ADAM™ rWBC HT, and ADAMII™.
Device for rapid microfluidic immunofluorescence analysis.
High-throughput fluorescence cell counting tool.
Accurate fluorescence-based cell counting device.
Counter for residual white blood cell detection.
Fluorescence counter for CD34 cell analysis.
People of NanoEntek
Unlock access to complete
Funding Insights of NanoEntek
Investments & Acquisitions by NanoEntek
Investment portfolio details for NanoEntek
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - NanoEntek
Detailed financials for NanoEntek
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Nanoentek Comparisons
Peer comparison for NanoEntek
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of NanoEntek
NanoEntek operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as GNA Biosolutions, NanoVation-GS, Tethis, Entopsis and ACXEL, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Instruments and assays for molecular pathogen detection are developed.
|
|
| Locked | Locked | Locked |
Nanomaterial-based sensors for respiratory monitoring devices are developed.
|
|
| Locked | Locked | Locked |
Automated solutions for liquid biopsy processing are provided.
|
|
| Locked | Locked | Locked |
Diagnostic devices for health monitoring are developed using specialized slides.
|
|
| Locked | Locked | Locked |
Microfluidic technology and solutions are provided for life sciences industries.
|
|
| Locked | Locked | Locked |
Developer of a lab on chip microfluidic platform for sequencing and molecular diagnostics using AI
|
Detailed competitors of NanoEntek
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Nanoentek
Complete news archive for NanoEntek
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about NanoEntek
NanoEntek was founded in 2000 and raised its 1st funding round 15 years after it was founded.
NanoEntek is headquartered in Seoul, South Korea.
As of Dec 31, 2024, the latest employee count at NanoEntek is 138.
Annual revenue of NanoEntek is $20.65M as on Dec 31, 2024.
NanoEntek was founded in 2000 in Seoul, South Korea, where point-of-care instruments for in vitro diagnostics and life science research are developed. Proprietary MEMS fabrication technologies are utilized in flagship products. Automated immunoassay solutions like FREND and BUDDI, ADAM for rWBC counting, and the JULI series for cell counting are offered. Reagents and kits for oncology and infectious diseases are provided alongside these instruments.
NanoEntek's top competitors include Tethis, GNA Biosolutions and Entopsis.
NanoEntek offers FREND™ System, EVE™ HT FL, ADAM™ MC Plus, ADAM™ rWBC HT, and ADAMII™.
Yes, NanoEntek is publicly traded on KRX under the ticker symbol 039860.
The ticker symbol of NanoEntek is 039860 on KRX.